New funding will strengthen Biosion’s “In Global For Global” positioning by accelerating its clinical pipeline and expanding its global biologics development teams

Newark, DE, Nanjing CN – Dec 9, 2021. Biosion Inc. (“Biosion”), a global, clinical-stage biotech company, today announced completion of a 200 million RMB preB+ financing round (including preB 2nd tranche financing) to accelerate discovery and global development of its innovative biologics portfolio targeting immunologic and cancer diseases. The financing was led by 3E Bioventures Capital, joined by Chase Capital. Concurrent with the financing, Mr. Lei Liu, the Director of 3E Bioventures Capital will join Biosion’s Board of Directors. Index Capital acts as the sole financial advisor for the current round of financing.

 “We are pleased to welcome 3E Bioventures Capital – a prestigious professional bio-venture capital firm – to join our effort in building our differentiated preclinical and clinical development portfolio, our global biologics development team and to further enable our strategy to be a leading “In Global For Global” biotech company” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion.

Dr. Karen Liu, Partner of 3E Bioventures Capital, said: “We believe GLOBALIZATION is the big theme for the next generation of biopharma. The capability of accessing a global talent pool, leveraging territorial clinical resources, and navigating through regional regulatory barriers is key to translating novel science from concept to product. We are excited and confident that Biosion is on the launchpad to lead this wave of industry change with its world-class leadership team.”

Through recent significant enhancement of the Executive Leadership team, Advisory Board and Global Development team, Biosion is now poised to substantially accelerate global clinical development efforts of its innovative biologics pipeline.

About Biosion, Inc.

Biosion is a leading “In Global For Global” clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive experience in global biologics development and built an oncology and auto-immune focused pipeline of innovative biologics through its internally-derived proprietary technologies, including the H3 hybridoma platform, SynAbTM synergistic antibody platform, SynTracerTM HT-endocytosis screening platform, and FlexibodyTM bispecific platform. Biosion’s mission is to discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftmanship for patients worldwide. Biosion is actively seeking global partners who are interested in licensing, partnership or co-development opportunities. For more information and full pipeline details, please visit www.biosion.com.

About 3E Bioventures Capital

3E Bioventures Capital is dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics. 3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency. The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.

About Chase Capital

Chase Capital is a professional investment institution focusing on early to mid-stage equity investment, with a core focus on two emerging industries, including biopharmaceutical and technology innovation. The funds managed by Chase Capital are mainly RMB funds and have invested in and incubated more than 20 domestic and foreign innovative companies, including HuiYu Pharmaceutical (688553), Harbour Biomed (02142) Elpiscience, Ab&b Bio-Tech, and other leading companies. With offices in Nanjing and Suzhou, Chase Capital focuses on the Yangtze River Delta region. Adhering to the concept of “focus on professionalism and accompany growth”, we hope to provide multi-faceted services for each partner company and help them grow into leading companies in the industry, as well as providing long-term development space and value recognition for investors and company partners.